N/A
Manufactured by Hospira, Inc.
4,806 FDA adverse event reports analyzed
Last updated: 2026-04-15
SUCCINYLCHOLINE CHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Hospira, Inc.. The most commonly reported adverse reactions for SUCCINYLCHOLINE CHLORIDE include DRUG INEFFECTIVE, HYPOTENSION, CARDIAC ARREST, ANAPHYLACTIC SHOCK, RENAL FAILURE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SUCCINYLCHOLINE CHLORIDE.
Out of 2,160 classified reports for SUCCINYLCHOLINE CHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 4,806 FDA FAERS reports that mention SUCCINYLCHOLINE CHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, HYPOTENSION, CARDIAC ARREST, ANAPHYLACTIC SHOCK, RENAL FAILURE, DRUG INTERACTION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Hospira, Inc. in connection with SUCCINYLCHOLINE CHLORIDE. Always verify the specific product and NDC with your pharmacist.